Skip to main content
Fig. 1 | Journal for ImmunoTherapy of Cancer

Fig. 1

From: EnanDIM - a novel family of L-nucleotide-protected TLR9 agonists for cancer immunotherapy

Fig. 1

Enantiomeric nucleotides as basis for EnanDIM® and their broad immune surveillance reactivation. a Nucleotides derived from D-ribose (top) and from L-ribose (bottom). b, schematic structure of linear EnanDIM® with their key structural components. c, time course of stability against exonuclease: Natural, or PTO-modified ODN, or L-nucleotide-protected EnanDIM® were incubated with T7 DNA-polymerase in the absence of NTP for the indicated times. Samples were subjected to gel electrophoresis (24% acrylamide), and DNA was visualized by ethidiumbromide. d, screening for IP-10 and IFN-alpha production: incubation of human PBMC with various EnanDIM® molecules differing in their nucleotide sequence as well as a reference molecule at a final concentration of 3 μM for 48 h in vitro. IP-10 and IFN-alpha values after stimulation with EnanDIM were normalized to the reference molecule (means from 3 to 26 different molecules): EnanDIM-A/-C are shown as black solid circles

Back to article page